BioCentury | Sep 21, 2017
Targets & Mechanisms

Appetite for GFRAL

...agonist; Orexigen Therapeutics Inc. ’s Contrave naltrexone/bupropion, a MOR antagonist; and Vivus Inc. ’s Qsiva phentermine/topiramate...
BioCentury | Jun 23, 2017
Clinical News

Novo’s semaglutide shows obesity benefit in Phase II trial

...side effects were the most common adverse events. Among obesity drugs launched over 2012-14, Qsymia phentermine/topiramate...
BioCentury | Mar 25, 2017
Strategy

Mountain climbing

...obesity product was Vivus Inc. ’s Qsymia , a low-dose combination of phentermine and topiramate. Qsymia...
BioCentury | Mar 7, 2016
Analyst Picks & Changes

Analyst picks & changes

...to $1 from $4. He said Vivus' financial position prevents it from commercially supporting Qsymia phentermine/topiramate...
...pharmacotherapies." Vivus ended 3Q15 with $300M in debt and $250M in cash. He thinks that Qsymia...
...FDA's requirement to run a postmarketing cardiovascular outcomes trial remains an overhang. Simeonidis estimates 2015 Qsymia...
BioCentury | Oct 5, 2015
Finance

Drawn and quartered

...it will further reduce the number of contractual sales representatives for its obesity drug Qsymia phentermine/topiramate...
...across the company. At the end of 1Q, the company announced plans to cut the Qsymia...
BioCentury | Sep 14, 2015
Finance

Gaining leverage

...eroding stock price is a reflection of the company's struggles to market obesity drug Qsymia phentermine/topiramate...
BioCentury | Aug 10, 2015
Company News

Vivus endocrine/metabolic news

...drug Qsymia phentermine/topiramate, this time to 50 from 100. During 1Q15, the company cut the Qsymia...
...it has met with FDA to discuss redesigning its AQCLAIM cardiovascular outcomes trial (CVOT) of Qsymia...
BioCentury | Aug 7, 2015
Company News

Orexigen amends Contrave deal, reports sales

...those of competing obesity drugs. Vivus Inc. (NASDAQ:VVUS) reported $14 million in 2Q15 sales of Qsymia...
BioCentury | Aug 1, 2015
Company News

Vivus to cut Qsymia sales force

...another 50 Qsymia sales positions last quarter. Vivus reported $14 million in 2Q15 sales of Qsymia...
...it has met with FDA to discuss redesigning its AQCLAIM cardiovascular outcomes trial (CVOT) of Qsymia...
...the consensus estimate of $0.24. Separately, Express Scripts Holding Co. (NASDAQ:ESRX) said it would exclude Qsymia...
BioCentury | Jul 13, 2015
Finance

Mid-cap hot streak

...NASDAQ:VVUS) NA $287.3 10.56 3/31/15 $6.8 Vivus reduced contractual sales representatives for obesity drug Qsymia phentermine/topiramate...
...it will further invest in "consumer-focused digital media projects" to raise awareness about obesity and Qsymia...
...specific guidance around anticipated savings. As of Feb. 6, Vivus had 94 employees, excluding contractual Qsymia...
Items per page:
1 - 10 of 346